I note that Bayer seem interested in "macrocyclic peptides" (rather than linear peptides).
I don't recall reading if PYC have a focus on any particular class of peptides. It may be that the PYC library (which is derived, if I understand correctly, from bacteria) is composed of linear (non-macrocyclic) peptides. In that case, it may not be of interest to Bayer.
Just some rambling, semi-incoherent thoughts....
FHC
PYC Price at posting:
3.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)